Clinical trials: Inflammatory
Inflammatory Bowel Diseases, Skin Extra-intestinal Manifestations
Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
The purpose of this phase 2a, proof of concept, open-label clinical study is to evaluate the efficacy and safety of etrasimod (APD334) in inflammatory bowel disease patients with active skin extra-intestinal manifestations.
- Trial name
- NCT03139032
- Testing
- APD334
- Where
- 3 sites in Belgium, Germany and 1 more
- Volunteers
- 1 people
- Sponsor
- Arena Pharmaceuticals
Crohn's Disease
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
REMICADE (infliximab) is a drug used to treat active Crohn's disease and is being tested in an experiment to see if it may be useful in preventing relapse of Crohn's disease after surgical resection.
- Trial name
- NCT01190839
- Testing
- Infliximab
- Where
- 142 sites in United States, Australia and 12 more
- Volunteers
- 297 people
- Sponsor
- Janssen Biotech, Inc.
Asthma Chronic
Inflammatory Indices in Predicting the Failure of Inhaled Corticosteroids Reduction in Young Participants With Asthma
A prospective, observational, interventional, single-blind study (blinded for a clinician in the field of inflammatory parameters).
- Trial name
- NCT03788057
- Testing
- ICS dose reduction
- Where
- Poland
- Volunteers
- 58 people
- Sponsor
- National Institute for Tuberculosis and Lung Diseases, Poland
Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
This phase Ib/II trial tests the safety and side effects of grapiprant and eribulin and whether they work to shrink tumors in patients with inflammatory breast cancer that has spread to other places in the body (metastatic).
- Conditions
- Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
- Trial name
- NCT05041101
- Testing
- Eribulin Mesylate, Grapiprant
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Inflammation, Ulcerative Colitis
A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis
This trial is conducted in Europe. The aim of the trial is to investigate the effect of recombinant factor XIII (rFXIII) administered to subjects with mild to moderate active ulcerative colitis (UC).
- Trial name
- NCT01706159
- Testing
- catridecacog
- Where
- 7 sites in Bulgaria, Croatia and 5 more
- Volunteers
- 20 people
- Sponsor
- Novo Nordisk A/S
Breast Cancer
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003042
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- City of Hope Medical Center
Colitis, Ulcerative
Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis
The purpose of this study is to evaluate the safety and effectiveness of trichuris suis ova (TSO) in ulcerative colitis (UC). We will look at how TSO affects the body's immune response and if there are related changes in…
- Trial name
- NCT01953354
- Testing
- Trichuris suis ova (TSO)
- Where
- 17 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atherosclerotic Vascular Disease, Type2 Diabetes
The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease
Experimental models have linked lipid lowering therapies with systemic inflammation; however, relatively little is known about this network in clinical populations and specifically how it changes with PCSK9 inhibition.
- Conditions
- Atherosclerotic Vascular Disease, Type2 Diabetes, Microvascular Dysfunction
- Trial name
- NCT03829046
- Testing
- Evolocumab
- Where
- 2 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Robert Rosenson
Breast Cancer
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
The main purpose is to learn if adding bevacizumab to standard chemotherapy and trastuzumab to treat HER2-positive breast cancer will affect heart function.
- Trial name
- NCT00464646
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- 36 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- NSABP Foundation Inc
Ulcerative Colitis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of…
- Trial name
- NCT06137183
- Testing
- Vixarelimab
- Where
- 65 sites in United States, Brazil and 10 more
- Volunteers
- 79 people
- Sponsor
- Genentech, Inc.
Ulcerative Colitis, Crohn's Disease
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
The main aim of the study is to learn if 4-weekly vedolizumab improves symptoms of Japanese participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD).
- Trial name
- NCT04738942
- Testing
- Vedolizumab
- Where
- 20 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Takeda
Septic Shock, Endotoxemia
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
To compare the safety and efficacy of the PMX cartridge based on mortality at 28-days in subjects with septic shock who have high levels of endotoxin and are treated with standard medical care plus use of the PMX cartridge…
- Trial name
- EUPHRATES (NCT01046669)
- Testing
- TORAYMYXIN PMX-20R (PMX cartridge), Standard medical care for septic shock
- Where
- 40 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- Spectral Diagnostics (US) Inc.
Crohn's Disease, Vitamin D Deficiency
Trial of High Dose Vitamin D in Patient's With Crohn's Disease
Crohn's disease is more common in areas of the world with less sunlight exposure. Sunlight is a major source of vitamin D. There is some research to suggest that patient's with higher vitamin D levels are less likely to undergo…
- Trial name
- RODIN-CD (NCT02208310)
- Testing
- Cholecalciferol 10,000 IU, Cholecalciferol 400 IU
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Michigan
Crohn's Disease, Ulcerative Colitis
Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease
Breastfeeding is beneficial to both mother and baby. However, many breastfeeding women are affected by long-term health conditions and need to take medications.
- Conditions
- Crohn's Disease, Ulcerative Colitis, Healthy Controls
- Trial name
- NCT03397108
- Testing
- The IBD group was divided into 2 subgroups: with or without anti-TNF antibody use
- Where
- 2 sites in Canada
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Juvenile Idiopathic Arthritis (JIA)
Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) in JIA
The study is a multicenter, double-blind, sham-controlled trial to evaluate the safety and effectiveness of tcVNS on pain and inflammation associated with JIA.
- Trial name
- AJA01 (NCT05710640)
- Testing
- Active tcVNS
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Obstructive Lung Disease
Effect of Symbicort ® on GR in Sputum in COPD
The purpose of the research (or "knowledge gap" this research is designed to fill) is to understand the science of how the combination therapy of 2 drugs (inhaled longacting beta-agonists(LABA) and inhaled corticosteroids (ICS)…
- Trial name
- NCT01787097
- Testing
- Symbicort® total dose 400ug/12ug, Symbicort® total dose 800ug/24ug, Formoterol 24ug
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Imperial College London
Crohn Disease
Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.
This study will evaluate the efficacy of capsule endoscopy (CE) versus ileocolonoscopy (IC) plus MRE for detection of active Crohn's disease (CD) in the small bowel in subjects with known CD and mucosal disease.
- Trial name
- BLINK (NCT03241368)
- Testing
- Capsule Endoscopy
- Where
- 26 sites in United States, Austria and 1 more
- Volunteers
- 187 people
- Sponsor
- Medtronic - MITG
Coronary Heart Disease
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP
This Phase 2a clinical trial evaluated the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, to reduce key markers of inflammation related to CVD…
- Trial name
- NCT06031844
- Testing
- DFV890
- Where
- 7 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease who completed the double-blind induction treatment in Study A3921083 and achieved clinical response-100 and/or…
- Trial name
- NCT01393899
- Testing
- CP-690,550
- Where
- 91 sites in United States, Australia and 15 more
- Volunteers
- 180 people
- Sponsor
- Pfizer
Crohn's Disease
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight loss, and fever.
- Trial name
- AIM-CD (NCT05068284)
- Testing
- ABBV-154
- Where
- 166 sites in United States, Australia and 22 more
- Volunteers
- 176 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.